Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

Solstice Oncology will gain an exclusive worldwide license to Harbour BioMed’s porustobrt, an anti-CTLA-4 antibody currently being studied for melanoma, colorectal cancer and other malignancies in ...

Deal involving an antibody asset 'goes beyond a traditional licensing transaction', founder and CEO says China's Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage ...

Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and ...

Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3 rd and will also host one-on-one meetings with investors. The event will be accessible to investors and interested ...

Sino-US biotech Harbour BioMed has announced a license agreement and equity partnership with Solstice Oncology, a clinical ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Heightened recognition and ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

BioMed Realty Trust continues to push the life sciences conversion wave in Boston, quietly taking over two prominent development sites. The Blackstone-backed life sciences investor has entered a ...

BioMed Realty, the largest private operator of real estate for the life science and technology industries, today announced that its Gateway of Pacific campus in South San Francisco has been named a ...